Fig. 7.

Efficacy of a sequential combination of olaparib with TAX2 in a peritoneal carcinomatosis model. ID8 Trp53^−/− Brca2.^−/− carcinoma cells were IP injected into mice as described in Fig. 6 to induce peritoneal carcinomatosis. At day 7 post inoculation, animals were randomly assigned (n = 7–11 per group) and treated with olaparib for 5 weeks (per os, daily at 50 mg/kg) or an equivalent volume of olaparib vehicle. Subsequently, mice were sequentially treated with TAX2 until the end of the protocol (IV, three times a week at 30 mg/kg). Kaplan–Meier overall survival analysis comparing control mice (black), olaparib-vehicle mice (gray), olaparib-treated mice (orange), and mice treated sequentially with olaparib then TAX2 (green) is presented. Statistical analysis was performed using the Gehan–Breslow–Wilcoxon test, denoted as *p < 0.05 and ***p < 0.001